Equities Analysts Offer Predictions for LRMR Q1 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Research analysts at Wedbush cut their Q1 2025 earnings estimates for shares of Larimar Therapeutics in a note issued to investors on Monday, March 24th. Wedbush analyst L. Chico now expects that the company will earn ($0.39) per share for the quarter, down from their prior estimate of ($0.25). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.52) EPS, FY2026 earnings at ($1.73) EPS and FY2027 earnings at ($1.17) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last released its earnings results on Monday, March 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

A number of other analysts also recently issued reports on LRMR. Guggenheim restated a “buy” rating and set a $26.00 price objective on shares of Larimar Therapeutics in a report on Tuesday. HC Wainwright raised their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday. Robert W. Baird dropped their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, Truist Financial assumed coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They set a “buy” rating and a $18.00 price objective for the company. Eleven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Larimar Therapeutics has an average rating of “Buy” and a consensus target price of $20.22.

Larimar Therapeutics Price Performance

Shares of Larimar Therapeutics stock opened at $2.31 on Wednesday. The firm has a market cap of $147.39 million, a PE ratio of -2.01 and a beta of 0.99. Larimar Therapeutics has a 1 year low of $2.22 and a 1 year high of $11.20. The stock has a fifty day moving average price of $3.14 and a 200-day moving average price of $5.20.

Hedge Funds Weigh In On Larimar Therapeutics

Several hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets bought a new position in Larimar Therapeutics in the 4th quarter worth about $25,000. Quest Partners LLC boosted its position in shares of Larimar Therapeutics by 171.1% in the third quarter. Quest Partners LLC now owns 9,183 shares of the company’s stock valued at $60,000 after acquiring an additional 5,796 shares during the period. Virtu Financial LLC bought a new position in shares of Larimar Therapeutics in the third quarter valued at approximately $71,000. Quarry LP increased its holdings in Larimar Therapeutics by 50.0% during the 3rd quarter. Quarry LP now owns 12,000 shares of the company’s stock worth $79,000 after acquiring an additional 4,000 shares during the period. Finally, Algert Global LLC purchased a new stake in Larimar Therapeutics in the 4th quarter worth approximately $47,000. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.